Relative safety of peginesatide and epoetin alfa

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 10, 2014, Pages 1003-1011

  Weinhandl, Eric D ^a   Gilbertson, David T ^a   Collins, Allan J ^a,b   Foley, Robert N ^a,b  

^a MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Claims; Dialysis; Erythropoiesis stimulating agent; Matching; Medicare; Pharmacoepidemiology

Indexed keywords

AMINOGLYCOSIDE; CEPHALOSPORIN; FERRIC GLUCONATE; IRON SACCHARATE; PEGINESATIDE; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; ERYTHROPOIETIN; PEPTIDE; RECOMBINANT PROTEIN;

ALGORITHM; ALL CAUSE HOSPITALIZATION; ARTICLE; BIOSURVEILLANCE; CARDIOVASCULAR MORBIDITY; COHORT ANALYSIS; DISEASE DURATION; DRUG EXPOSURE; DRUG SAFETY; EMERGENCY HEALTH SERVICE; END STAGE RENAL DISEASE; FOLLOW UP; HEALTH CARE CONCEPTS; HEMODIALYSIS PATIENT; HIGH RISK POPULATION; INCIDENCE; MATCHING ALGORITHM; MEDICARE; MORBIDITY; MORTALITY; PATIENT CARE; PERITONEAL DIALYSIS; PHARMACOSURVEILLANCE; RISK FACTOR; ADVERSE EFFECTS; ANEMIA; CLINICAL TRIAL (TOPIC); FACTUAL DATABASE; FEMALE; HUMAN; MALE; MIDDLE AGED; RENAL REPLACEMENT THERAPY; STATISTICS AND NUMERICAL DATA;

ANEMIA; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; DATABASES, FACTUAL; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; MALE; MIDDLE AGED; PEPTIDES; RECOMBINANT PROTEINS; RENAL DIALYSIS;

EID: 84911806742     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3655     Document Type: Article

References (17)

1. Omonty. Omontys prescribing information. 3-27-2012. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202799s000lbl.pdf [14 April 2014].
2. Fishbane S, Schiller B, Locatelli F, et al. Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med 2013; 368: 307-319.
3. Omonty. Omonty's New Drug Application 202799 - Approval Letter. 3-27-2012. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/202799Orig1s000ltr.pdf [14 April 2014].
4. Omonty. Omontys prescribing information. 12-4-2012. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202799s001lbl.pdf [14 April 2014].
5. Omonty. Omontys Safety Alert. 2-23-2013. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm340895.htm [14 April 2014].
6. Chiu YW, Teitelbaum I, Misra M, et al. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol 2009; 4: 1089-1096.
7. McAdams MA, Governale LA, Swartz L, et al. Identifying patterns of adverse event reporting for four members of the angiotensin II receptor blockers class of drugs: revisiting the Weber effect. Pharmacoepidemiol Drug Saf 2008; 17: 882-889.
8. Strom BL, Kimmel SE, Hennessy S. Pharmacoepidemiology (5th edn). Wiley-Blackwell: Oxford, 2012.
9. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43: 1130-1139.
10. Hebert PL, Geiss LS, Tierney EF, et al. Identifying persons with diabetes using Medicare claims data. Am J Med Qual 1999; 14: 270-277.
11. Nordstrom BL, Norman HS, Dube TJ, et al. Identification of abacavir hypersensitivity reaction in health care claims data. Pharmacoepidemiol Drug Saf 2007; 16: 289-296.
12. D'Agostino RB, Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-2281.
13. Austin PC. Using the standardized difference to compare the prevalence of binary variable between two groups in observation research. Commun Stat Simul Comput 2009; 38: 1228-1234.
14. Macdougall IC, Provenzano R, Sharma A, et al. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med 2013; 368: 320-332.
15. Boven K, Stryker S, Knight J, et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 2005; 67: 2346-2353.
16. U.S. Renal Data System: USRDS. Annual Data Report: Atlas of Chronic Kidney Disease & End-Stage Renal Disease in the United States, 2013 ed, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2013.
17. Federal Register. Details for Regulation Number: CMS-1418-F. Federal Register 75(155). 2010. Available at: http://www.gpo.gov/fdsys/pkg/FR-2010-08-12/pdf/2010-18466.pdf [14 April 2014].